Investigation launched into GeneDx after Q1 earnings miss and 41% stock drop

Levi & Korsinsky has started an investigation into GeneDx Holdings Corp. for possible federal securities law violations following the company's Q1 2026 earnings report. GeneDx had forecasted positive adjusted net income for all of 2026, but reported a loss of $8.2 million in Q1 with adjusted EPS of -$0.28, far below the expected -$0.01. This earnings miss caused the stock to plunge between 41% and 49%. Investors who suffered losses may seek recovery through the investigation.